<?xml version="1.0" encoding="UTF-8"?>
<p id="Par104">An interim analysis will be conducted when 55 patients have a minimal follow-up of 6 months. We will monitor the efficacy endpoint using the Bayesian optimal phase 2 (BOP2) design [
 <xref ref-type="bibr" rid="CR62">62</xref>]. Specifically, let 
 <italic>n</italic> denote the interim sample size and 
 <italic>N</italic> denote the maximum sample size. Let 
 <italic>p</italic>
 <sub>
  <italic>eff</italic>
 </sub> denote the probability of efficacy (response rate) and define the null hypothesis 
 <italic>H</italic>
 <sub>0</sub> : 
 <italic>p</italic>
 <sub>
  <italic>eff</italic>
 </sub> &lt; 0.84, representing that the treatment is inefficacious. We will stop enrolling patients and claim that the treatment is not promising if 
 <disp-formula id="Equa">
  <alternatives>
   <tex-math id="M1">\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \mathit{\Pr}\left({p}_{eff}\ge 0.84\mid data\right)&lt;\lambda {\left(\frac{n}{N}\right)}^{\alpha }, $$\end{document}</tex-math>
   <math id="M2" display="block">
    <mo mathvariant="italic">Pr</mo>
    <mfenced close=")" open="(">
     <mrow>
      <msub>
       <mi>p</mi>
       <mi mathvariant="italic">eff</mi>
      </msub>
      <mo>≥</mo>
      <mn>0.84</mn>
      <mo>∣</mo>
      <mtext mathvariant="italic">data</mtext>
     </mrow>
    </mfenced>
    <mo>&lt;</mo>
    <mi>λ</mi>
    <msup>
     <mfenced close=")" open="(">
      <mfrac>
       <mi>n</mi>
       <mi>N</mi>
      </mfrac>
     </mfenced>
     <mi>α</mi>
    </msup>
    <mo>,</mo>
   </math>
   <graphic xlink:href="12885_2021_8195_Article_Equa.gif" position="anchor" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  </alternatives>
 </disp-formula>where 
 <italic>λ</italic> =0.95 and 
 <italic>α</italic> =1 are design parameters optimized to minimize the chance of incorrectly claiming that an efficacious treatment is not promising (i.e., type II error) under the alternative hypothesis 
 <italic>H</italic>
 <sub>1</sub> : 
 <italic>p</italic>
 <sub>
  <italic>eff</italic>
 </sub> = 0.92, while controlling the type I error rate at 0.05 (i.e., the chance of incorrectly claiming that an inefficacious treatment is promising is no more than 5%). Assuming a Beta (0.84,0.16) prior distribution for 
 <italic>p</italic>
 <sub>
  <italic>eff</italic>
 </sub>, if more than 10 patients among the 55 patients develop recurrences, the trial will be stopped in the interim analysis. Otherwise, the trial will be continued.
</p>
